Safety and efficacy of intravenous thrombolysis in stroke patients on prior antiplatelet therapy in the WAKE-UP trial

Benedikt M. Frey 1*, Florent Boutitie 2,3,4, Bastian Cheng 1, Tae-Hee Cho 5, Martin Ebinger 6,7, Matthias Endres 6,8, Jochen B. Fiebach 6, Jens Fiehler 9, Ian Ford 10, Ivana Galinovic 6, Alina Königsberg 1, Josep Puig 11, Pascal Roy 2,3,4, Anke Wouters 12,13,14, Tim Magnus 1, Vincent Thijs 15,16, Robin Lemmens 12,13,14, Keith W. Muir 17, Norbert Nighoghossian 5, Salvador Pedraza 11, Claus Z. Simonsen 18, Christian Gerloff 1, Götz Thomalla 1 and on behalf of the WAKE-UP investigators

Abstract

Background: One quarter to one third of patients eligible for systemic thrombolysis are on antiplatelet therapy at presentation. In this study, we aimed to assess the safety and efficacy of intravenous thrombolysis in stroke patients on prescribed antiplatelet therapy in the WAKE-UP trial.

Methods: WAKE-UP was a multicenter, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of MRI-guided intravenous thrombolysis with alteplase in patients with an acute stroke of unknown onset time. The medication history of all patients randomized in the WAKE-UP trial was documented. The primary safety outcome was any sign of hemorrhagic transformation on follow-up MRI. The primary efficacy outcome was favorable functional outcome defined by a score of 0–1 on the modified Rankin scale at 90 days after stroke, adjusted for age and baseline stroke severity. Logistic regression models were fitted to study the association of prior antiplatelet treatment with outcome and treatment effect of intravenous alteplase.

Results: Of 503 randomized patients, 164 (32.6%) were on antiplatelet treatment. Patients on antiplatelet treatment were older (70.3 vs. 62.8 years, \( p < 0.001 \)), and more frequently had a history of hypertension, atrial fibrillation, diabetes, hypercholesterolemia, and previous stroke or transient ischemic attack. Rates of symptomatic intracranial hemorrhage and hemorrhagic transformation on follow-up imaging did not differ between patients with and without antiplatelet treatment. Patients on prior antiplatelet treatment were less likely to achieve a favorable outcome (37.3% vs. 52.6%, \( p = 0.014 \)), but there was no interaction of prior antiplatelet treatment with intravenous alteplase concerning favorable outcome (\( p = 0.355 \)). Intravenous alteplase was associated with higher rates of favorable outcome in patients on prior antiplatelet treatment with an adjusted odds ratio of 2.106 (95% CI 1.047–4.236).

(Continued on next page)
(Continued from previous page)

**Conclusions:** Treatment benefit of intravenous alteplase and rates of post-treatment hemorrhagic transformation were not modified by prior antiplatelet intake among MRI-selected patients with unknown onset stroke. Worse functional outcome in patients on antiplatelets may result from a higher load of cardiovascular co-morbidities in these patients.

**Keywords:** Ischemic stroke, Alteplase, Thrombolysis, Recombinant human tissue plasminogen activator, Rt-PA, Aspirin, Clopidogrel, Hemorrhagic transformation, Antiplatelet, WAKE UP

**Background**
Approximately one quarter to one third of all patients receiving intravenous thrombolytic therapy with alteplase (recombinant human tissue plasminogen activator, rt-PA) for the treatment of acute ischemic stroke are on prescribed antiplatelet treatment (APT) [7, 10, 15]. The fact that both antiplatelets and alteplase interfere substantially with the natural hemostasis raises concern about an increased risk of hemorrhagic complications, and in the ARTIS trial a high rate of symptomatic intracerebral hemorrhage (sICH) was observed with simultaneous administration of intravenous alteplase and aspirin [20]. However, neither in current guidelines, nor in clinical practice, is prior APT considered as an exclusion criterion to treatment with alteplase [9, 19].

Several studies have explored the potential association of antiplatelet treatment with hemorrhagic complications in the context of acute thrombolysis for stroke. In this context, it’s important to distinguish between different categories of intracranial hemorrhage following ischemic stroke. Whereas sICH and parenchymal hemorrhage type 2 (PH2) seem to be related to biologic effects of alteplase and clinically relevant for the patients, the haemorrhagic transformation of infarcted brain tissue might just be an epiphenomenon of ischemic damage and reperfusion [14, 16]. Recent meta-analyses unanimously found APT to be significantly associated with higher risk of subsequent intracerebral hemorrhage (ICH) or sICH in patients treated with rt-PA. In contrast, evidence regarding a possible interaction as to functional outcome remains contradictory [4, 7, 15, 17].

WAKE-UP was a randomized, double-blind, placebo-controlled trial on efficacy and safety of MRI-based thrombolysis in wake-up stroke [12]. The trial protocol comprised follow-up MRI at 22–36 h, enabling the detection of even small and asymptomatic ICH following thrombolysis. In the present secondary post hoc analysis of the WAKE-UP trial data, we aimed at studying the efficacy and safety of intravenous thrombolysis among patients on APT.

**Methods**

**Study design**
Inclusion criteria for the WAKE-UP trial comprised the mismatch between an acute ischemic lesion visible on diffusion weighted imaging (DWI) and no corresponding marked parenchymal hyperintensity on fluid-attenuated inversion recovery (FLAIR). Preceding studies endorsed this mismatch as a surrogate marker of lesion age, indicating that the stroke onset most likely lies within 4.5 h [13]. All patients or their legal representatives provided written informed consent according to national and local regulations and the competent authorities for each study site and the corresponding ethics committee approved the trial. Analysis of MR images and assessment of hemorrhagic transformation was done centrally by a central image reading board. The detailed trial protocol was published together with its main results [12]. For the present post hoc analysis, all data on the medical history of patients randomized in WAKE-UP was reviewed to identify participants with medication history that included current APT prescription. The agents screened for were as follows: Aspirin, Clopidogrel, Dipyridamol, Triflusal (Single-non-aspirin), Ticagrelor, Prasugrel, Ticlopidine and Eptifibatide. Both single and dual therapy were separately recorded. Furthermore, demographic characteristics and clinical data at baseline and follow-up were collected for statistical analysis.

**Outcome measures and endpoints**
Primary safety outcome was the occurrence of any hemorrhagic transformation on follow-up imaging 22–36 h after treatment, corresponding to HI-1, HI-2, PH-1 and PH-2 in the Heidelberg bleeding classification [16]. The definition of sICH was according to the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS–MOST) local or remote PH-2 plus neurologic deterioration, as indicated by a score on the NIHSS that was higher by 4 points or more than the baseline value or the lowest value between baseline and 24 h, or hemorrhage leading to death. The evaluation of the efficacy results was based on the clinical endpoints as defined in the WAKE-UP study, whereby clinical outcome was assessed at 90 days after stroke. The primary endpoint was favorable outcome defined as a score of 0–1 on the modified Rankin scale (mRS). Secondary endpoint was a shift towards a better functional outcome across the entire range of the mRS ("shift analysis").
Statistical analysis
At first, baseline characteristics between patients with and without APT prescription were compared. The statistical analyses of treatment effects were performed in the intention-to-treat population for all patients with available information for clinical endpoints.

For the safety and primary efficacy variables, we calculated unconditional logistic regression models to estimate the odds ratio and its 95% confidence interval (CI). The categorical shift in the distribution of mRS scores was analyzed by fitting a proportional-odds logistic regression model. To investigate the interaction between APT and treatment effect of alteplase, an according interaction term was included in the models. All models fitted were adjusted for the stratification parameters age and NIHSS at randomization. As all analyses were considered exploratory, all tests were carried out with a two-sided alpha level of 5% without correction for multiple comparisons.

Results
Patient characteristics
Of 503 randomized patients, 164 patients (32.6%) were on APT. Of these, 134 patients (81.7%) were pretreated with aspirin, 34 patients (20.7%) with clopidogrel, 6 patients (3.7%) with dipyridamole, 1 patient (0.6%) with triflusal, and 11 (6.7%) patients were pretreated with two antiplatelets. For the latter, aspirin was prescribed in all cases, combined with clopidogrel in 7 patients and with dipyridamol in 4 patients. Patients on APT were older (mean age 70.3 vs. 62.8 years, \( p < 0.001 \)), and were more likely to have a medical history of smoking, hypertension, atrial fibrillation, diabetes mellitus type II, hypercholesterolemia, previous ischemic stroke and transient ischemic attacks (all \( p < 0.001 \), see Table 1). Consistent with this, patients with prior APT showed higher rates of simultaneous pretreatment with antidiabetic drugs, antihypertensives, and statins. Other baseline characteristics were comparable between patients with and without prior APT.

Information on the primary and secondary efficacy endpoints was available for 490 participants. Of these, 246 and 244 were randomized to treatment with alteplase and placebo, respectively. The proportion of patients on prior APT in the alteplase group (\( n = 75 \), 30.5%) was comparable to the placebo group (\( n = 86 \), 35.2%, \( p = 0.290 \)). Information on the primary safety endpoint and the secondary safety endpoint PH-2 hemorrhage was available for 496 participants. Information on the secondary safety endpoint sICH according to SITS–MOST was available for 503 participants.

Safety outcomes in patients with antiplatelet pretreatment
Prior APT was not associated with higher risk of any radiological hemorrhagic transformation (24.5% vs 23.7%, adjusted OR 0.84, 95% CI 0.63–1.36; \( p = 0.478 \)). There was no significant difference between either groups regarding the occurrence of sICH (2.4% vs 0.6%; adjusted OR 2.84, 95% CI 0.50–16.05; \( p = 0.238 \)). In the group with APT, 5 patients (3.1%) showed PH-2 hemorrhage on follow-up imaging, compared to 6 patients (1.8%) in the group of patients without prior APT (adjusted OR 1.17, 95% CI 0.34–4.09; \( p = 0.806 \)).

Interaction of antiplatelet pretreatment and treatment safety of alteplase
The general low frequency of sICH and PH-2 hemorrhage in our cohort did not allow for statistical modelling. Treatment with alteplase was associated with

| Variable                                      | Prior APT (n = 164) | No prior APT (n = 339) | \( P \) Value |
|-----------------------------------------------|---------------------|------------------------|--------------|
| Age, mean (SD), years                         | 70.3 (8.2)          | 62.8 (12.1)            | < 0.001      |
| Female sex, No. (%)                           | 60 (36.6)           | 118 (34.8)             | 0.692        |
| Time between last seen well and symptom recognition, median (IQR), hours | 7.52 (5.00–8.50)    | 7.00 (4.67–9.50)       | 0.085        |
| Medical history/risk factors, No. (%)         |                     |                        |              |
| Arterial hypertension                         | 120 (73.2)          | 146 (43.1)             | < 0.001      |
| Diabetes mellitus                             | 44 (26.8)           | 38 (11.2)              | < 0.001      |
| Hypercholesterolemia                          | 98 (59.8)           | 80 (23.6)              | < 0.001      |
| Atrial fibrillation                            | 27 (16.5)           | 32 (9.4)               | 0.010        |
| History of ischemic stroke                    | 52 (31.7)           | 16 (4.7)               | < 0.001      |
| History of TIA                                | 17 (10.4)           | 6 (1.8)                | < 0.001      |
| Current or former smoker                      | 94 (58)             | 162 (50)               | 0.009        |
| NIHSS score, median (IQR)                     | 6 (4–12)            | 5 (4–9)                | 0.104        |
| DWI lesion volume at baseline, median (IQR), ml | 2.28 (0.80–9.61)    | 2.23 (0.70–7.70)       | 0.506        |

SD standard deviation, IQR interquartile range, TIA transient ischemic attack, NIHSS National Institute of Health Stroke Scale, DWI diffusion weighted imaging
higher odds of any hemorrhagic transformation among all randomized patients, but there was no significant interaction effect of thrombolysis with prior APT ($p = 0.631$). The adjusted OR for any hemorrhagic transformation with alteplase was 2.27 (95% CI 1.05–4.90) in patients with prior APT and 1.803 (95% CI 1.05–3.10) in patients without prior APT (Fig. 1).

**Interaction of antiplatelet pretreatment and treatment effect of alteplase**

Patients on APT treatment - independent of thrombolysis treatment group - had lower rates of favorable outcome (37.3 vs. 52.6%; adjusted OR 0.58, 95% CI 0.38–0.89; $p = 0.014$). Treatment with alteplase was associated with higher odds of favorable outcome among all randomized patients with no significant interaction between thrombolysis and prior APT ($p = 0.355$). The adjusted OR for favorable outcome with alteplase was 2.11 (95% CI 1.05–4.24) in patients with prior APT and 1.417 (95% CI 0.89–2.26) in patients without prior APT (Fig. 2).

Prior APT – independent of treatment group - was associated with a significant shift on the mRS towards worse outcomes (adjusted OR 1.56, 95% CI 1.10–2.23; $p = 0.014$). Treatment with alteplase was associated with a shift on the mRS towards better functional outcome among all randomized patients, but there was no significant interaction of thrombolysis with prior APT ($p = 0.309$). The adjusted OR for a shift on the mRS towards better outcomes with alteplase was 2.00 (95% CI 1.16–3.46) in patients with prior APT and 1.410 (95% CI 0.95–2.09) in patients without prior APT (Fig. 3).

**Discussion**

In a post-hoc analysis of the WAKE-UP trial we studied the effect of prescribed antiplatelet therapy prior to stroke on functional outcome and safety outcomes overall, and on the efficacy and safety of intravenous alteplase in acute stroke patients with unknown time of symptom onset. There were two main findings. First, prior antiplatelet therapy was associated with a worse functional outcome independent of treatment, but not with higher rates of symptomatic intracerebral hemorrhage or radiological signs of hemorrhagic transformation. Second, pretreatment with antiplatelets did not alter the beneficial effect or the safety of intravenous alteplase.

In our sample about one in three patients was pretreated with antiplatelets, which is comparable to prior studies on this topic in patients with known time of symptom onset [7, 15]. This reflects the high load of cardiovascular risk factors and co-morbidities in patients with acute stroke, as shown by a history of arterial hypertension in 53%, hypercholesterolemia in 35%, diabetes in 16%, and prior ischemic stroke in 14% of the patients in our study population. Thus, antiplatelets are commonly prescribed among patients treated with intravenous thrombolysis for acute ischemic stroke, and data on the hemorrhagic risk of this thrombolytic treatment in these patients are helpful to inform clinical practice.

Patients on APT treatment had a worse functional outcome in our sample – even after adjustment for age and baseline NIHSS. This might be explained by the higher load of co-morbidities in patients on APT and
Fig. 2 Effect of alteplase on favorable outcome. Forest plots demonstrate a higher chance of a favorable functional outcome for patients treated with alteplase in both patients with prior APT and without. There was no significant interaction in the corresponding unconditional logistic regression model.

Fig. 3 Distribution of modified Rankin scale scores at 90 days after stroke. Distributions of scores on the modified Rankin scale show a favoring of the alteplase group over the placebo group. Modified Rankin scale scores range from 0 to 6 (0, no symptoms; 1, no clinically significant disability; 2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe disability; 6, death). Numbers indicate rounded proportions. There was no significant interaction in the corresponding unconditional logistic regression model.
the known association of more severe co-morbidities and worse functional outcome after stroke [3, 11]. Nevertheless, results from previous studies are contradictory with regard to the association of pretreatment with antiplatelets and outcome of intravenous thrombolysis. Some previous studies with systemic thrombolysis showed a similar association of APT with worse functional outcome as observed in our analysis [4, 7, 10]. In contrast, a meta-analysis of randomized trials of intravenous thrombolysis revealed no significant association of APT and functional outcome after correction for age and stroke severity [15]. These contradictory findings may result from differences in clinical characteristics of the study samples and/or adjusting for varying baseline predictors.

For clinical practice, the question whether APT interacts with the treatment effect of intravenous thrombolysis, is even more important. We did not observe any interaction of prior APT with the treatment effect of alteplase, neither regarding favorable outcome, nor when considering functional outcome across the entire range of the mRS. Intravenous alteplase had a significant beneficial effect on functional outcome within the subgroup of patients with prior APT, a finding which strongly supports the current practice that does not consider antiplatelet treatment as a contraindication for intravenous thrombolysis. To the best of our knowledge, this explicit exclusion of a statistical interaction with the effects of thrombolysis is novel and adds substantially to the available research on pre-treatment with antiplatelets and alteplase.

The main concern regarding pretreatment with antiplatelets in patients receiving intravenous alteplase refers to ICH, as there is in general an increased risk of ICH in stroke patients on prior APT, independently of thrombolysis: in a Korean registry of 10,433 patients with acute and subacute ischemic stroke, there were higher adjusted odds of hemorrhagic transformation on MRI at presentation in patients on prior APT [8].

The numbers of radiologically severe and symptomatic ICH after intravenous thrombolysis in our study were small, most likely an artefact of the general low severity in the MRI-selected population of the WAKE-UP trial. Therefore, we decided to study any hemorrhagic transformation detected by follow-up MRI after 22–36 h. Among all randomized patients, intravenous thrombolysis was significantly associated with a higher risk of developing any hemorrhagic transformation, which is a well-known phenomenon linked to the biological effects of alteplase. However, in our study patients on APT treatment did not show higher rates of hemorrhagic transformation, nor did prior APT interact with alteplase with regard to the rates of hemorrhagic transformation. These findings are in line with a metaanalysis, in which no association of APT with sICH was observed after correction for patient-level characteristics [15]. In contrast, other previous studies found prior APT to be associated with increased rates of ICH [10, 17] and sICH [3, 4, 6, 7, 10, 18] in patients treated with thrombolysis. Again, these contradictory findings may result from differences in clinical characteristics of the study samples.

There are limitations to our study. The number of clinical relevant symptomatic intracranial hemorrhages was small in both groups, so our study was underpowered to detect differences between the groups with regard to these important safety outcomes. Therefore, we cannot exclude a potential difference in both groups, nor can we exclude an interaction with alteplase with respect to safety.

Moreover, due to the small numbers of patients taking more than one antiplatelet drug, we were not able to study the potential effect of double antiplatelet treatment on safety and efficacy of treatment with intravenous alteplase in our cohort. Whereas a post-hoc analysis of the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register found a combination of aspirin and clopidogrel associated with higher rates of sICH, a recent meta-analysis, however, revealed no significant risk of sICH, 3-month mortality or worse favourable outcome after 3 months in these patients [1, 5, 6]. The numbers of patients taking other antiplatelet drugs than aspirin was also small in our cohort, so that we could not study specific risks of different antiplatelet agents. However, a previous study with a comparable distribution of aspirin, clopidogrel and other antiplatelet agents found no specific differences on severity of stroke at presentation, in-hospital mortality and mRS at discharge [2].

Conclusion

To summarize, in the randomized controlled WAKE-UP trial, treatment with intravenous alteplase was safe and efficient in patients with unknown onset stroke on prior antiplatelet therapy, even though the latter might be a predictor of worse functional outcome. Intravenous thrombolysis should not be withheld from patients with unknown onset acute ischemic stroke on prior antiplatelet therapy.

Abbreviations

APT: AntiPlatelet Treatment; ICH: IntraCerebral Hemorrhage; MRI: Magnetic Resonance Imaging; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; OR: Odds Ratio; sICH: symptomatic IntraCerebral Hemorrhage

Acknowledgements

The WAKE-UP investigators and administrative staff are as follows: Götz ThomaUla, MD; Christian Gerloff, MD; Amir Golsari, MD; Anna Alegiani, MD; Bastian Cheng, MD; Christoph Beck, MD; Chi-un Choe, MD; Dieke Vogt, MD; Julia Hoppe, MD; Julian Schröder, MD; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Martin Ebinger, MD; Karl Georg Häusler, MD; Michal
Germany; Rainer Kollmar, MD; Josef Schill, MD; Anna-Mareike Löbbe; Klinikum Darmstadt, Darmstadt, Germany; Thierry Moulin, PhD; Benjamin Bouarana; Louise Bonnet, MD; Hôpital Jean Minjoz, Besançon, France; Emmanuel Touzé, PhD; Anne-Laure Bonnet, MD; Emmanuel Touze, PhD; Julien Cogez, MD; Lin Li, MD; Sophie Guettier, MD; CHU de Caen, Caen, France; Arindam Kat, MD; Aravindh Sivagnanarathnam; Olivia Geraghty, MD; Urszula Bojańczy; Charing Cross Hospital London, London, UK; Arumugam Nallasivan, MD; Countess of Chester Hospital, Chester, UK; Miguel Blanco Gonzales, MD; Manuel Rodríguez-Yáñez, PhD; Hospital Clínico Universitario de Santiago de Compostela, Santiago, Spain; Jose Temblí; David Gomez; Hospital Universitario Politécnico de La Fe de Valencia, Valencia, Spain; Stefan Oberndorfer, MD; Elisabeth Prohaska, MD; Universitätssklinikum St. Pölten, St. Pölten, Austria.

Role of funder / sponsor
The European Union Seventh Framework Program (FP7/2007–2013) had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Authors’ contributions
Benedikt M. Frey had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Benedikt M. Frey, Florent Boutitie and Götz Thomalla conducted the data analysis. The author(s) read and approved the final manuscript.

Funding
WAKE-UP received funding from the European Union Seventh Framework Program (FP7/2007–2013) under grant agreement n°278276 (WAKE-UP).

Availability of data and materials
Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.

Ethics approval and consent to participate
All patients or their legal representatives provided written informed consent according to national and local regulations and the competent authorities for each study site and the corresponding ethics committee approved the trial.

Consent for publication
All patients or their legal representatives provided written informed consent according to national and local regulations.

Competing interests
EB reports grants from the German Parkinson Society and ACTELION Pharmaceuticals Deutschland GmbH, outside the submitted work. FB reports grants from University Medical Center Hamburg-Eppendorf during the conduct of the study. ME reports grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Coviden, Ever, Novartis, all outside the submitted work. JFR reports personal fees from Bioclinica, Artemida, Cerevac, and Nicol outside the submitted work. TM receives grants from DFG, BMBF, the Schilling Foundation, Merck-Serono and Grifols, outside the submitted work. VT reports personal fees and non-financial support from Boehringer Ingelheim, Pfizer/BMS, Bayer, Syngis, Amgen and Allergan outside the submitted work. KWM reports personal fees and non-financial support from Boehringer Ingelheim outside the submitted work. CZS reports grants from Novo Nordisk Foundation and personal fees from Bayer outside the submitted work. CG reports personal fees from AMGEN, Bayer Vital, BMS, Boehringer Ingelheim, Sanofi Aventis, Abbott, and Prediction Biosciences outside the submitted work. GT reports personal fees from Acascid, Boehringer Ingelheim, BMS/Pfizer, Stryker, Portola, Daiichi Sankyo, grants and personal fees from Bayer, grants from Corona Foundation, German Innovation Fonds and Else Kroener Fresenius Foundation outside the submitted work. All remaining authors declare no competing interests.

Author details
1Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany; 2Hospices Civils de Lyon, Service de Biostatistique, F-69003 Lyon, France; 3Université Lyon 1, F-69100 Villeurbanne, France; 4CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, F-69100 Villeurbanne, France; 5Department of Stroke Medicine, Universität Claude Bernard Lyon 1, 1, CREATEIS CNRS UMR 5220-INSERM U1206, INSAY-Lyon, Hospices Civils de Lyon, Lyon, France; 6Centrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany; 7Neurologie der Rehaklinik Medical Park Humboldtmühle, An der Mühle 2-9, 13507 Berlin, Germany; 8Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany; 9Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany; 10Robinson Centre for Biostatistics, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK; 11Department of Radiology, Institut di Diagnostic per la Image (IDI), Hospital Dr Josep Tuetu, Institut d’Investigació Biomèdica de Girona (IDIBGI), Parc Hospitalari Martí i Julià de Salt - Edifici M2, 17910 Salt, Girona, Spain; 12Department of Neurology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium; 13Department of Neurosciences, Experimental Neurology, KU Leuven – University of Leuven, Dode Markt 13, bus 5005, 3000 Leuven, Belgium; 14VIB, Center for Brain & Disease Research, Laboratory of Neurobiom, Campus Gasthuisberg, Herestraat 49, bus 602, 3000 Leuven, Belgium; 15Florey Institute of Neuroscience and Mental Health, University of Melbourne, 245 Burungundy Street, Heidelberg, VC 3084, Australia; 16Department of Neurology, Austin Health, 145 Studley Road, Heidelberg, VC 3084, Australia; 17Institute of Neuroscience & Psychology, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK; 18Department of Neurology, Aarhus University Hospital, 8200 Aarhus N, Denmark.

Received: 11 June 2020 Accepted: 1 September 2020

Published online: 20 November 2020

References
1. Diedler, J., Ahmed, N., Sykora, M., Uyttenboogaart, M., Overgaard, K., Luijckx, G. J. J., Ringleb, P. (2010). Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antplatelet therapy at stroke onset. Stroke, 41(2), 288–294. https://doi.org/10.1161/STROKEAHA.109.559724.
2. Dovlatshahi, D., Hakim, A., Fang, J., Sharma, M., & Investigators of the Registry of the Canadian Stroke Network (2009). Pre admission antithrombotics are associated with improved outcomes following ischemic stroke: a cohort from the registry of the Canadian stroke network. International Journal of Stroke : Official Journal of the International Stroke Society, 4(5), 328–334. https://doi.org/10.1111/j.1747-4949.2009.00331.x.
3. Goldstein, L. B., Sambs, G. P., Matchar, D. B., & Hornor, R. D. (2004). Charlson index comorbidity adjustment for ischemic stroke outcome studies. Stroke, 35(8), 1941–1945. https://doi.org/10.1161/01.STR.0000135225.80898.1c.
4. Luo, S., Zhuang, M., Zeng, W., & Tao, J. (2016). Intravenous thrombolysis for acute ischemic stroke in patients receiving antplatelet therapy: a systematic review and meta-analysis of 19 studies. Journal of the American Heart Association, 5(5), e003242. https://doi.org/10.1161/JAHA.116.003242.
5. Malhotra, K., Katsanos, A. H., Goyal, N., Ahmed, N., Strbian, D., Palaiodimou, L., … Tsivgoulis, G. (2020). Safety and efficacy of dual antplatelet pretreatment in patients with ischemic stroke treated with IV thrombolysis: a systematic review and meta-analysis. Neurology, 94(7), e657–e666. https://doi.org/10.1212/WNL.0000000000008961.
6. Mayza, M., Egidio, J. A., Ford, G. A., Lees, K. R., Mikulik, R., Toni, D., … Ahmed, N. (2012). Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous Alteplase. Stroke, 43(6), 1524–1531. https://doi.org/10.1161/STROKEAHA.111.644815.
7. Pan, X., Zhu, Y., Zheng, D., Liu, Y., Yu, F., & Yang, J. (2015). Prior antplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials. International Journal of Stroke : Official Journal of the International Society Stroke, 10(3), 317–323. https://doi.org/10.1111/ijs.12431.
8. Park, J.-M., Kang, K., Cho, Y.-J., Hong, K.-S., Lee, K. B., Park, T. H., … Bae, H.-J. (2016). Comparative effectiveness of prestroke aspirin on stroke severity and outcome. Annals of Neurology, 79(4), 560–568. https://doi.org/10.1002/ana.24602.
9. Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., … Tirschwell, D. L. (2019). Guidelines for the early management
of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 50(12), e544–e418. https://doi.org/10.1161/STR. 0000000000000211.

10. Robinson, T. G., Wang, X., Arima, H., Bath, P. M., Billot, L., Broderick, J. P., … Anderson, C. S. (2017). Low- versus standard-dose Alteplase in patients on prior antiplatelet therapy. Stroke, 48(7), 1877–1883. https://doi.org/10.1161/ STROKEAHA.116.016274.

11. Simić-Panić, D., Bošković, K, Milićević, M, Žikic, T. R, Bošnjak, M. C, Tomasevic-Todorovic, S, & Jovicic, M. (2018). The impact of comorbidity on rehabilitation outcome after ischemic stroke. Acta Clinica Croatica, 57(1), 5–15. https://doi.org/10.20471/acc.2018.57.01.01.

12. Thomalla, G., Simonsen, C. Z., Boutitie, F., Andersen, G., Billot, L., Broderick, J. P., … Anderson, C. S. (2017). Low- versus standard-dose Alteplase in patients on prior antiplatelet therapy. Stroke, 48(7), 1877–1883. https://doi.org/10.1161/STROKEAHA.116.016274.

13. Thomalla, G., Cheng, B., Ebinger, M., Hao, Q., Tourdias, T., Wu, O., … Geloff, C. (2011). DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurology, 10(11), 978–986. https://doi.org/10. 1016/S1474-4422(11)70192-2.

14. Thomalla, G., Sobesky, J., Köhrmann, M., Fiebach, J. B., Fiehler, J., Weber, O. Z., … Schellinger, P. D. (2007). Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia - MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke, 38(2), 313–318. https://doi.org/10.1161/01.STR.0000254565.51807.22.

15. Tsvigoulis, G., Katsanos, A. H., Zand, R., Sharma, V. K., Köhrmann, M., Giannopoulos, S., … Alexandrov, A. V. (2017). Antplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis. Journal of Neurology, 264(6), 1227–1235. https://doi.org/10. 1007/s00415-017-8520-1.

16. von Kummer, R., Broderick, J. P., Campbell, B. C. V., Demchuk, A., Goyal, M., Hill, M. D., … Hacke, W. (2015). The Heidelberg bleeding classification. Stroke, 46(10), 2981–2986. https://doi.org/10.1161/STROKEAHA.115.010049.

17. Whiteley, W. N., Slot, K. B., Fernandes, P., Sandercock, P., Sanderson, J., & Wardlaw, J. (2012). Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis of 55 studies. Stroke. https://doi.org/10.1161/STROKEAHA. 112.665331.

18. Xian, Y., Federspiel, J. J., Grau-Sepulveda, M., Hernandez, A. F., Schwamm, L. H., Bhatt, D. L., … Peterson, E. D. (2016). Risks and benefits associated with prestroke antiplatelet therapy among patients with acute ischemic stroke treated with intravenous tissue plasminogen activator. JAMA Neurology, 73(1), 50–59. https://doi.org/10.1001/jamaneurol.2015.3106.

19. Zerna, C, Thomalla, G., Campbell, B. C. V., Rha, J. H., & Hill, M. D. (2018, October 1). Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. The Lancet. Lancet Publishing Group. https://doi.org/10.1016/S0140-6736(18)31874-9.

20. Zinkstok, S. M., & Roos, Y. B. (2012). Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. The Lancet, 380(9843), 731–737. https://doi.org/10.1016/S0140- 6736(12)60949-0.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.